Intuitive Surgical (ISRG) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $154B
- As of Nov 13, 2026
- P/E
- 52.03x
- Trailing twelve months
- P/B
- 9.63x
- Latest reported equity
- P/S
- 13.30x
- Trailing twelve months
- ROE
- 18.5%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $154B
- As of Nov 13, 2026
- P/E
- 52.03x
- Trailing twelve months
- P/B
- 9.63x
- Latest reported equity
- P/S
- 13.30x
- Trailing twelve months
- ROE
- 18.5%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
52.03x
P/B
9.63x
P/S
13.30x
Earnings and dividend metrics▾
Earnings
EPS
$8.53
Earnings per share
BPS
$46.07
Book value per share
ROE
18.5%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $8.53 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $46.07 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 18.5%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 21.7% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $2.51B+21.7%
$2.04B
Jul–Sep '24
$2.51B
Jul–Sep '25
$3.05B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 21, 2026.
- Earnings per share decreased 23.6% from the same quarter a year earlier.
- Revenue increased 21.7% from the same quarter a year earlier.
- Operating income decreased 22.0% from the same quarter a year earlier.
- Net income decreased 25.7% from the same quarter a year earlier.
Filed Oct 21, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- LOEB GARYEVP & Chief Legal and Complian · Nov 10, 2026Open-market sale400 shares · $183KAvg. price $458.156,236 shares held after
- GUTHART GARY SDirector · Nov 4, 2026Open-market sale10,000 shares · $4.6MAvg. price $457.3371,194,530 shares held after
- BARRATT CRAIG HDirector · Nov 4, 2026Open-market sale1,150 shares · $529KAvg. price $460.00260 shares held after
- BARRATT CRAIG HDirector · Nov 4, 2026Option exercise1,150 shares · $104KAvg. price $90.49441,150 shares held after
- Widman FredrikVP Corporate Controller · Oct 30, 2026Open-market sale5,448 shares · $2.4MAvg. price $436.05511,026 shares held after
- Brosius MarkEVP & Chief Mfg and Supply Cha · Oct 30, 2026Open-market sale63 shares · $29KAvg. price $453.6457 shares held after
- Widman FredrikVP Corporate Controller · Oct 30, 2026Option exercise5,448 shares · $1.1MAvg. price $201.0747
Show 14 price lots
- 406 shares × $347.4167$141K
- 567 shares × $242.3367$137K
- 567 shares × $177.9867$101K
- 406 shares × $245.6$100K
- 307 shares × $304.67$94K
- 312 shares × $290.33$91K
- 307 shares × $229.39$70K
- 312 shares × $208.9$65K
- 543 shares × $109.4856$59K
- 325 shares × $174.2567$57K
- 263 shares × $182.8333$48K
- 325 shares × $139.52$45K
- 262 shares × $166.6233$44K
- 546 shares × $79.6378$43K
- Brosius MarkEVP & Chief Mfg and Supply Cha · Oct 29, 2026Open-market sale61 shares · $27KAvg. price $447.85520 shares held after
- Brosius MarkEVP & Chief Mfg and Supply Cha · Oct 28, 2026Open-market sale61 shares · $27KAvg. price $441.6581 shares held after
- Brosius MarkEVP & Chief Mfg and Supply Cha · Oct 27, 2026Open-market sale61 shares · $28KAvg. price $451.63642 shares held after
- Brosius MarkEVP & Chief Mfg and Supply Cha · Oct 26, 2026Open-market sale61 shares · $28KAvg. price $451.75703 shares held after
- GUTHART GARY SDirector · Oct 23, 2026Open-market sale20,095 shares · $9.1MAvg. price $451.61171,204,530 shares held after
- Widman FredrikVP Corporate Controller · Oct 23, 2026Open-market sale4,047 shares · $1.8MAvg. price $453.20591,026 shares held after
- BARRATT CRAIG HDirector · Oct 23, 2026Open-market sale1,150 shares · $510KAvg. price $443.80 shares held after
- WADORS PATRICIA LSVP Chief Human Resources Offi · Oct 23, 2026Open-market sale1,078 shares · $478KAvg. price $443.80 shares held after
- Widman FredrikVP Corporate Controller · Oct 23, 2026Option exercise4,047 shares · $927KAvg. price $229.1439
Show 11 price lots
- 406 shares × $347.4167$141K
- 567 shares × $242.3367$137K
- 567 shares × $177.9867$101K
- 406 shares × $245.6$100K
- 307 shares × $304.67$94K
- 312 shares × $290.33$91K
- 307 shares × $229.39$70K
- 325 shares × $174.2567$57K
- 263 shares × $182.8333$48K
- 325 shares × $139.52$45K
- 262 shares × $166.6233$44K
- BARRATT CRAIG HDirector · Oct 23, 2026Option exercise1,150 shares · $104KAvg. price $90.49441,150 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KThe company said its Board approved on October 29, 2026 an increase in the Board's size from 10 to 11 members and appointed Aaron Martin effective January 1, 2027. Martin will not be assigned to any committees as of the effective date.Published Nov 2, 2026 · Filed Nov 2, 2026Read the summary →
- AI summary10-QIntuitive said total da Vinci procedures grew about 14% in Q3 2026. U.S. procedures rose about 10%, and procedures outside the U.S. (OUS) rose about 20%. For Q3 2025, total procedure growth was about 19%.Published Oct 21, 2026 · Filed Oct 21, 2026Read the summary →
- AI summary8-KThe company said its Q3 2026 revenue rose to $3.05 billion from $2.51 billion in Q3 2025, an increase of 22%. It placed 546 da Vinci systems in the same quarter, compared with 427 a year earlier.Published Oct 20, 2026 · Filed Oct 20, 2026Read the summary →
- The company said its Board approved on October 29, 2026 an increase in the Board's size from 10 to 11 members and appointed Aaron Martin effective January 1, 2027. Martin will not be assigned to any committees as of the effective date.Read the full analysis →
- Intuitive said total da Vinci procedures grew about 14% in Q3 2026. U.S. procedures rose about 10%, and procedures outside the U.S. (OUS) rose about 20%. For Q3 2025, total procedure growth was about 19%.Read the full analysis →
- The company said its Q3 2026 revenue rose to $3.05 billion from $2.51 billion in Q3 2025, an increase of 22%. It placed 546 da Vinci systems in the same quarter, compared with 427 a year earlier.Read the full analysis →
- The company said da Vinci procedures performed by its customers grew about 15% over the 3 months ended June 30, 2026, lower than about 17% a year earlier. U.S. procedures grew about 12%, and procedures outside the U.S. (OUS) grew about 20%.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Intuitive Surgical (ISRG) stock information
NASDAQ
Intuitive Surgical (ISRG) is listed on NASDAQ. Its market capitalization is about $154B. On trailing-twelve-month earnings the P/E ratio is 52.03, and the P/B ratio is 9.63. Return on equity is 18.5%. These figures are computed in-house from official filings and are reference information only.
Intuitive Surgical — frequently asked questions
- What is the P/E ratio of Intuitive Surgical (ISRG)?
- On a trailing-twelve-month basis, ISRG trades at a P/E ratio of 52.03. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Intuitive Surgical?
- ISRG has a market capitalization of about $154B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.